Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
230.6 USD | +2.17% | -2.57% | -10.87% |
Jun. 12 | Biogen executive plays down looming competition for its Alzheimer's drug | RE |
Jun. 12 | BIOGEN EXEC SAYS THE ALZHEIMER'S DRUG MARKET "WILL DEVELOP FASTE… | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.87% | 33.58B | |
+0.30% | 91.38B | |
-2.37% | 38.68B | |
+71.42% | 27.84B | |
-12.31% | 16.05B | |
-4.54% | 13.48B | |
-10.83% | 11.73B | |
+180.20% | 10.74B | |
-48.60% | 10.39B | |
+1.42% | 8.94B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen, Ionis to Cease BIIB105 ALS Investigational Drug Development Following Phase 1/2 Trial Results